SCHEDULE: CASI Pharma Secures $5M Convertible Note for China Trials

CASI Pharmaceuticals, Inc. has secured a $5 million convertible promissory note from ETP Global III Fund LP to fund clinical trials in China and general operations.

Summary

• CASI Pharmaceuticals, Inc. issued a US$5,000,000 convertible promissory note to ETP Global III Fund LP.
• The note bears a simple interest rate of 12% per annum, payable quarterly, with the first payment due July 1, 2026.
• The maturity date for the note is January 8, 2029.
• Both the Holder (ETP Global III Fund LP) and the Company have the option to convert the outstanding principal and accrued interest into Ordinary Shares.
• The conversion price will be the volume-weighted average closing price of the Company's Ordinary Shares over the five trading days preceding the conversion notice, subject to a floor of US$1.00 and a ceiling of US$2.00 per share.
• The proceeds from this note will primarily be used for clinical trials in China for CID-103 and general company operations, with restrictions on significant U.S. clinical trial investments without Holder approval.
• This US$5 million note represents the second tranche of a US$20 million convertible note financing.
• Wei-Wu He, Ph.D., beneficially owns 13,965,535 shares, representing 45.4% of the class, including shares convertible from this and a previous note.
• ETP Global Fund III L.P. beneficially owns 10,000,000 shares, representing 32.7% of the class, including shares convertible from this and a previous note.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it secures necessary funding for key clinical trials, but the high interest rate and subordination indicate a higher cost of capital and potential risks.

Positives

• Secured US$5 million in financing, providing capital for clinical trials and general operations.
• The financing is specifically earmarked for value-creating milestones for CID-103 in China.
• The convertible nature of the note offers flexibility for both the company and the investor.

Negatives

• The 12% annual interest rate is relatively high, indicating a significant cost of capital.
• The note is unsecured and subordinate to the Company's secured debt, increasing risk for the holder.
• Restrictions on using proceeds for significant U.S. clinical trials without Holder approval could limit strategic flexibility.

Risks

• Default Risk: Failure to repay the outstanding balance by the Maturity Date, insolvency, appointment of a receiver, failure to pay interest, breach of the Purchase Agreement or Note, or knowingly incorrect material representations can trigger an Event of Default.
• Subordination Risk: The note is general unsecured debt and is subordinate to the Company's secured debt, meaning secured creditors would be paid first in case of liquidation.
• Dilution Risk: Conversion of the note into Ordinary Shares will dilute existing shareholders' ownership.
• Conversion Price Volatility: The conversion price is based on the volume-weighted average closing price, which can fluctuate, potentially leading to conversion at a less favorable price for the company (but capped at $1.00 floor).
• Regulatory Risk: The securities have not been registered under the Securities Act of 1933, and sales or dispositions must comply with applicable laws or exemptions.

Future Outlook

The Company intends to substantially employ the proceeds from this convertible note for clinical trials in China, specifically targeting value-creating milestones for CID-103, and for general operational expenses. There are restrictions on significant investments in U.S. clinical trials without the Holder's prior written approval.

Management Comments

• The Company hereby promises to pay to the order of ETP Global III Fund LP... the principal sum of US$5,000,000... on January 8, 2029...
• The proceeds from this Note will be substantially employed by the Company for clinical trials in China to achievement of value-creating milestones for CID-103 and general operation of the Company.

Industry Context

StockSavvy.ai notes that securing non-dilutive debt financing, even convertible debt, is a common strategy for biotechnology companies like CASI Pharmaceuticals, especially those focused on specific regional markets like China for clinical development. The high interest rate suggests a higher risk profile or limited alternative financing options, which is not uncommon for companies in the clinical stage. The focus on CID-103 in China aligns with a strategy to leverage specific market opportunities.

Comparison to Industry Standards

• The 12% interest rate on a convertible note is on the higher end compared to typical corporate debt for established pharmaceutical companies, reflecting the inherent risks of clinical-stage biotech or smaller market capitalization firms. For example, larger biotech firms might secure convertible debt in the 2-6% range, while early-stage companies might see rates from 8-15% depending on market conditions and company specifics.
• The conversion price floor of US$1.00 and ceiling of US$2.00 provides a defined range, which is a common feature in convertible notes to protect both the issuer from excessive dilution at very low prices and the investor from conversion at very high prices.
• The use of proceeds for clinical trials in China for CID-103 is standard for a biopharmaceutical company aiming to advance its pipeline in a key growth market. Many global pharmaceutical companies, such as AstraZeneca or Pfizer, also conduct extensive clinical trials in China, often through local partnerships or subsidiaries, to tap into the large patient population and regulatory pathways.

Related Party Transactions

• The convertible note was issued to ETP Global III Fund LP, which is part of a group of reporting persons including Wei-Wu He, Ph.D., who is the founder and managing partner of ETP and its related funds, and also a significant beneficial owner of CASI Pharmaceuticals. This indicates a related-party transaction.

Stakeholder Impact

• Shareholders: Potential for dilution upon conversion of the note into Ordinary Shares. The high interest rate represents a cost to the company that could impact future earnings.
• Creditors: The note is unsecured and subordinate to secured debt, meaning other creditors with secured claims would have priority.
• Employees: Continued funding for operations and clinical trials helps ensure job stability and progress on pipeline assets.
• Customers/Patients: Funding for CID-103 clinical trials in China could lead to new treatment options if successful.

Next Steps

• Interest payments on the note will commence on July 1, 2026, and continue quarterly.
• The Holder has the option to convert the note into Ordinary Shares from the 91st day after the Closing Date until the Maturity Date.
• The Company has the option to convert the note into Ordinary Shares at maturity.
• The Company will continue to use the proceeds for clinical trials for CID-103 in China and general operations.

Key Dates

Recommendation

The financing provides necessary capital for critical clinical trials, which is a positive for the company's long-term prospects. However, the high interest rate and the inherent risks of clinical-stage drug development, coupled with potential dilution from conversion, suggest a 'hold' recommendation. Investors should monitor the progress of CID-103 trials and the company's overall financial health.

Keywords

CASI Pharmaceuticals, Convertible Note, Financing, SEC Filing, CID-103, Clinical Trials China, ETP Global III Fund LP, Debt Financing, Biotechnology, Pharmaceuticals, Corporate Governance, Schedule 13D